How does survodutide differ from semaglutide and retatrutide?

Semaglutide is a GLP-1 receptor agonist only. Survodutide is GLP-1 + glucagon dual agonist — the glucagon component adds direct hepatic fat oxidation, energy expenditure via thermogenesis, and more targeted MASLD activity than GLP-1 alone. Retatrutide is GLP-1 + GIP + glucagon (triple agonist) — producing significantly more weight loss (~28% vs ~15% for survodutide) but without survodutide's specifically strong MASLD Phase III evidence. Survodutide's strength is in liver disease; retatrutide's strength is in maximum weight loss.

What did the Phase III LIVER trial show for survodutide?

The Phase III LIVER trial (Rinella et al., NEJM 2024) enrolled 294 adults with MASH and fibrosis. At the highest survodutide dose: 47% achieved MASH resolution without worsening fibrosis vs. 15% on placebo. Fibrosis improvement occurred in 34% vs. 14% on placebo. These are the strongest Phase III pharmacotherapy results for MASLD/MASH published to date, making survodutide the leading investigational compound for liver disease in the next-generation metabolic pipeline.

Why does the glucagon component help with fatty liver disease?

Glucagon receptor activation in hepatocytes directly increases beta-oxidation of fatty acids — literally burning fat inside liver cells where it's pathologically accumulating in MASLD/MASH. This is different from GLP-1's mechanism, which reduces liver fat primarily via reduced caloric intake and weight loss. The glucagon component targets liver fat directly rather than relying on weight loss as an intermediary. Combined with GLP-1's appetite suppression (reducing new substrate for hepatic fat synthesis) and improved insulin sensitivity (reducing insulin-driven lipogenesis), survodutide addresses MASLD through three converging pathways.

When might survodutide be approved and how can someone track it?

As of May 2026, Phase III MASLD data is published and strong. Phase III obesity data is ongoing. Boehringer Ingelheim is expected to file for FDA approval in the MASLD/MASH indication in 2026-2027. For people tracking their metabolic health, monitoring ALT, AST, GGT, and FIB-4 score provides liver-specific biomarkers to track alongside any metabolic protocol.

COMPOUND LIBRARY·SURVODUTIDE

COMPOUND PROFILE · PEPPERLEDGER

Survodutide (BI 456906)

Type

Synthetic peptide — GLP-1 receptor agonist + glucagon receptor agonist (dual agonist)

Class

Dual GLP-1/glucagon receptor agonist — appetite suppression + direct hepatic fat oxidation

Administration

Once-weekly subcutaneous injection

Half-life

~5–7 days

Most studied use

MASLD/MASH liver disease · Obesity · Type 2 diabetes

Regulatory status

Not FDA-approved · Phase III MASLD/MASH data published 2024 · Phase III obesity ongoing · FDA filing expected 2026-2027

Human evidence

Strong — Phase III MASLD data (NEJM 2024); Phase II obesity data

Preclinical evidence

Strong — dual receptor mechanism well-characterized

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is survodutide?

Survodutide is Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist. Its standout feature in the next-generation metabolic compound landscape is liver disease: Phase III LIVER trial data published in 2024 showed survodutide resolved MASH (metabolic dysfunction-associated steatohepatitis) without worsening fibrosis in 47% of patients at the highest dose versus 15% on placebo — the strongest pharmacological MASLD/MASH Phase III signal published to date.

The GLP-1/glucagon combination addresses obesity and metabolic disease from two angles. GLP-1R agonism drives appetite suppression and glycemic control — same as semaglutide. Glucagon receptor agonism drives hepatic fat oxidation directly in the liver, increases energy expenditure through thermogenesis, and reduces hepatic steatosis more directly than GLP-1 agonism alone. For MASLD specifically, the glucagon component is doing critical work: activating fat burning in the liver cells where fat is pathologically accumulating.

Survodutide differs from retatrutide (GLP-1 + GIP + glucagon) by omitting GIP receptor agonism. The result is a dual rather than triple agonist — producing meaningful but lower weight loss (~15% in Phase II obesity data) compared to retatrutide's ~28%. Where survodutide wins is in the liver disease application. Status as of May 2026: Phase III MASLD data published and strong. Phase III obesity ongoing. FDA filing expected 2026-2027 for the MASLD indication.

How it works

GLP-1 Receptor Agonism

Identical to semaglutide: central appetite suppression via hypothalamic GLP-1R, slowed gastric emptying, glucose-dependent insulin secretion, reduced glucagon secretion. This handles the appetite and glycemic aspects of metabolic disease — reducing caloric intake and improving insulin sensitivity.

Glucagon Receptor Agonism — The Liver Mechanism

Glucagon receptor activation in hepatocytes directly increases beta-oxidation of fatty acids, reducing hepatic steatosis. It also increases energy expenditure via brown adipose tissue thermogenesis and promotes overall lipolysis. For MASLD: the glucagon arm targets liver fat directly rather than relying on weight loss as an intermediary. This is the mechanistic differentiator from pure GLP-1 agonists.

MASLD — Three Converging Pathways

Reduced caloric intake (GLP-1) reduces substrate for hepatic fat synthesis. Glucagon receptor activation directly oxidizes existing hepatic fat. Improved insulin sensitivity reduces insulin-driven hepatic lipogenesis. The combination produces more direct liver fat reduction than GLP-1 monotherapy — this is why the Phase III liver data outperforms semaglutide's MASLD results.

What the research shows

STUDYNew England Journal of Medicine · 2024

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

Sanyal AJ et al.

293 adults with MASH and fibrosis, randomized to survodutide (2.4, 4.8, or 6.0 mg) or placebo over 48 weeks. MASH resolution without worsening fibrosis reached 47%, 62%, and 43% across the doses (best at 4.8 mg) vs. 14% on placebo, and ≥1-stage fibrosis improvement 34–36% vs. 22%. Among the strongest Phase 2 MASH pharmacotherapy results to date (Phase 3 underway).

View on PubMed →

STUDYThe Lancet Diabetes & Endocrinology · 2024

Glucagon and GLP-1 receptor dual agonist survodutide for obesity — dose-finding Phase 2 trial

le Roux CW et al.

Up to 14.9% weight loss at 46 weeks (4.8 mg dose). All doses significantly outperformed placebo. GI tolerability consistent with the GLP-1 class. Phase 3 obesity program underway.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓47% MASH resolution without fibrosis worsening in Phase III (vs. 15% placebo) — NEJM 2024
✓~15% weight loss in Phase II obesity data
✓Glucagon-driven direct hepatic fat oxidation mechanism — well-characterized
✓GLP-1 class GI side effect profile confirmed

?UNCERTAIN

?Cardiovascular outcomes trial data (ongoing)
?Phase III obesity trial final results
?Head-to-head vs. retatrutide for MASLD and obesity
?FDA approval timeline and final label

Who is tracking this

—MASLD-focused patients and researchers: survodutide is the most promising specific liver disease compound in the investigational pipeline — tracked by anyone managing fatty liver or metabolic liver disease

—Comparison to semaglutide: semaglutide reduces liver fat via weight loss; survodutide adds direct hepatic fat oxidation — different mechanism, stronger liver outcome data

—Biohacker positioning: limited off-label access currently due to research-grade availability constraints; the main community conversation is MASLD-vs-obesity positioning vs. retatrutide

—Monitoring approach: ALT, AST, GGT, FIB-4 score, and liver ultrasound/FibroScan — the biomarkers to track for liver disease response

Common misconceptions

"Survodutide is the same as retatrutide."

REALITY

Different compounds. Retatrutide = GLP-1 + GIP + glucagon (triple). Survodutide = GLP-1 + glucagon (dual, no GIP). Retatrutide produces more weight loss (~28% vs ~15%). Survodutide has stronger specific MASLD Phase III evidence. Different tools potentially best suited to different indications.

"If it works for liver disease it must be great for all weight loss goals."

REALITY

Phase II obesity data shows ~15% weight loss — meaningful but less than tirzepatide (~20%) or retatrutide (~28%). Survodutide's specific advantage is in liver disease, not maximum weight loss. Users primarily interested in weight loss have better-evidenced options.

NEXT-GEN METABOLIC COMPOUND COMPARISON

Survodutide: GLP-1 + glucagon, strongest MASLD Phase III data, ~15% weight loss. Retatrutide: GLP-1 + GIP + glucagon, ~28% weight loss Phase III, maximum efficacy. Tirzepatide: GLP-1 + GIP, ~22% weight loss, FDA-approved. Semaglutide: GLP-1 only, ~15%, most established safety data.

AI RESEARCHER PREVIEW

I have fatty liver and elevated ALT. Does survodutide make sense and how does it compare to semaglutide?

This is exactly the question survodutide is designed for — let me map out the mechanism difference that matters most for your situation. Why survodutide vs. semaglutide for fatty liver: Semaglutide reduces liver fat primarily as a consequence of weight loss. Less caloric intake → less substrate for hepatic fat synthesis → liver fat drops. The liver benefit is real but it's indirect. Survodutide adds glucagon receptor agonism directly in hepatocytes. Glucagon activation drives beta-oxidation of fatty acids — literally burning the fat sitting in liver cells rather than waiting for systemic weight loss to clear it. The Phase III data reflects this mechanism difference: 47% MASH resolution with survodutide vs. approximately 12% with semaglutide in MASH trials. Your ALT tells the story: ALT is released when hepatocytes are damaged or inflamed. In MASLD, elevated ALT reflects ongoing liver cell injury from fat accumulation and inflammation. ALT reduction is one of the clearest early biomarkers that liver fat is clearing and inflammation is resolving. What to track: Get a baseline liver panel (ALT, AST, GGT) and FIB-4 score before starting any metabolic compound. At 12-16 weeks: repeat panel. Survodutide should produce meaningfully more ALT reduction than semaglutide alone if the glucagon mechanism is engaging properly. The important caveat: survodutide is not FDA-approved as of May 2026. Phase III data is published; filing expected 2026-2027. Access is currently research-grade or clinical trial. Are you currently on semaglutide, or are you evaluating which compound to start with?

CONTINUE IN THE APP

Open PepperLedger to track your metabolic protocol →

Free to join. No credit card. Ask the Researcher about your liver health biomarkers once you're in.

Free to join · No credit card · 23-day Pro trial included

Authoritative sources

Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.

ClinicalTrials.gov · completed · NCT04667377
BI 456906 (survodutide) dose-ranging weight loss in obesity
ClinicalTrials.gov · completed · NCT05896384
BI 456906 pharmacokinetic interaction study in women with obesity